INTRODUCTION 22
Despite initially high remission rates, at least 75% of women diagnosed with advanced 23 stage epithelial ovarian carcinoma (EOC) will relapse and ultimately die of their disease [1] . 24 Treatment of these patients once they develop recurrent disease remains a major problem. The 25 need for new therapeutic strategies is evident. The SRC family of kinases (SFK) is a nine 26 member group of membrane associated non-receptor tyrosine kinases that are involved in a 27 variety of cellular signaling pathways [2] . The SFK is involved in the oncogenesis of numerous 28 tumors including ovarian cancer. SRC regulates many intracellular signaling pathways 29 responsible for various important tumor cell functions such as proliferation, motility and invasion, 30 angiogenesis, and survival. SRC has been found to be overexpressed in a majority of late 31
stage ovarian tumors and cell lines [3] . 32 SRC is a component of signaling pathways downstream of many growth factor 33 receptors, including epidermal growth factor receptor (EGFR), vascular endothelial growth factor 34 receptor (VEGFR), and MNNG transforming gene product (c-MET) [4] . Increased resistance to 35 traditional chemotherapy is modulated by SRC through increased activity of RAS and AKT [5] . 36
Inhibition of SRC enhanced the activity of cytotoxic agents, including cisplatin, gemcitabine, and 37 paclitaxel through the activation of caspase-3 in pre-clinical models [5] [6] [7] . In addition, tumor 38 growth was blunted when human ovarian cancer cells carrying an antisense SRC construct 39 were implanted into mice bearing these xenografts [8] . 40 VEGF is an important growth factor for ovarian cancer cells [9] . VEGF was significantly 41 down-regulated by SRC inhibition and microvessel density was reduced [10] . Anti-VEGF 42 therapy has demonstrated activity in patients with recurrent and primary disease [11, 12] . VEGF 43 stimulation of its receptor increased tyrosine phosphorylation of focal adhesion kinase, p130 44 CAS and paxillin [13] . Increased activity of these mediators leads to an increased epithelial-to-45 6 mesenchymal transition (EMT), a crucial step to enhancing the metastatic potential of these 46 cancer cells [14] . SRC is a key intermediate in the EMT process [15, 16] . In addition, caveolin-1 47 expression indirectly promotes cell-cell adhesion in ovarian cancer cells [17, 18] . SRC interferes 48 with caveolin function also promoting EMT and encouraging tumor spread. 49
Dasatinib is a potent oral inhibitor of breakpoint cluster region-Abelson fusion protein 50 (BCR-ABL), c-KIT, ephrin type-A receptor 2 (EPHA2), c-FMS, and SFK [19, 20] . These kinases 51 are implicated in oncogenic process and maintaining the metastatic phenotype of many 52 cancers. Dasatinib's mechasnism of action depends on itsuccessfully competing for the ATP 53 binding site contained in the kinase domain. The agent is widely approved for chronic 54 myelogenous leukemia and Ph+ acute lymphoblastic leukemia and is now under investigation 55 for treating various solid tumors [21] . 56
Based on these observations, the evaluation of dasatinib in patients with recurrent EOC 57 was undertaken by the Gynecologic Oncology Group (GOG). Translational research objectives 58 were included to explore the association between biomarkers and patient outcome. [22] , a GOG performance status of 0-2, and adequate bone marrow (absolute 68 neutrophil count ≥1,500/µL, platelet count ≥100,000/µL), renal (serum creatinine ≤1.5 x the 69 upper limit of normal), and hepatic function (total bilirubin ≤1. early data that solid tumors may require higher doses of dasatinib to achieve clinical activity 107 compared with the doses used to treat patients with CML [23, 24] . 108
Response Assessment 109
Patients were evaluated clinically every four weeks and radiographically every eight 110 weeks. The same evaluation modality was used throughout for each patient on study. 111
Response criteria used were as defined by RECIST [22] . 112 113
Translational Research 114
Plasma and whole blood specimens were collected for translational research prior to cycles 1, 2 115 and 3. Detailed methodology and references for isolating and phenotyping CTC and CEC/CEP 116 can be found in the supplemental material [online only]. Methods for determining circulating 117 levels of serum biomarkers and extraction and quantification of total plasma cell-free DNA 118 (cfDNA) are also summarized in the supplemental online material. 119
Statistical Methods 120
We anticipated that the effect of dasatinib might be either cytotoxic or cytostatic. 121 Therefore, the primary endpoint of this study included both objective tumor response and the 122 proportion of patients alive and progression-free after six months PFS-6). Time on study was 123 assessed from date of registration and included all eligible treated patients. 124
The null hypothesis, i.e. an "uninteresting" level of efficacy, was determined from 125 analysis of an historical GOG dataset, based on a similar patient population from clinical trials of 126 study drugs now considered inactive or minimally active. The null hypothesis jointly specified 127 the probability of a patient experiencing a tumor response to be ≤10% and the probability of a 128 patient being alive and free from PFS-6 to be ≤15%. For the purpose of study design, a 20% 129 increase (to 25% for tumor response or to 35% for PFS-6) were considered clinically significant. 130
The two-stage, bivariate, flexible method of Sill and Yothers [25] There were no responders. Also, only seven patients (20.6%; 90% confidence interval: 150 10.1%, 35.2%) were PFS-6 (Table 2) . Therefore, the protocol criteria for continuing to the 151 second stage of accrual were not met. Of the seven patients with PFS ≥6 months, five had two 152 prior treatment regimens while two had received one prior regimen, and all had platinum-153 resistant disease (<6 months platinum-free interval) Median PFS was 2.1 months (first and third 154 quartiles: 1.8 and 4.9 months). Median overall survival (OS) was 17.7 months (first quartile: 155 10.8 months, third quartile has not been reached; Figure 1) . 156
Toxicity 157
The most commonly observed grade 3 toxicities were gastrointestinal (mostly nausea 158 and emesis), pulmonary (dyspnea and/or pleural effusion), and pain (Table 3 ). There were 159 single cases of grade 3 or 4 anemia, malaise, insomnia, rash, and central nervous system 160 hemorrhage. 161 
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Translational research 163
Dasatinib related biomarkers 164
Bead-based immunoassays were used to measure circulating levels of seven dasatinib 165 related biomarkers in plasma collected pre-cycles 1 (n=27), 2 (n=23), and 3 (n=15). Fifteen 166 patients submitted samples at all three time points. Median biomarker levels (ng/mL) are 167 presented (Supplemental Table S1 ). There was a significant increase in the levels of 168 sVEGFR2, sVGEFR3, and IGFBP2 between baseline and pre-cycle three in these patients. 169
There was no association between baseline levels of plasma biomarkers and outcome (PFS 170 and OS) nor between changes in biomarker levels and six-month PFS outcome (data not 171 shown). 172
Circulating cfDNA 173
Total cfDNA from plasma collected pre-cycles 1 (n=28), 2 (n=23), and 3 (n=15) was 174 quantified using a real-time PCR TaqMan Assay and primers directed to β-actin, β-globin, and 175 GAPDH. Median cfDNA totals (GE/mL) are presented (Supplemental Table S2 ). cfDNA 176 increased from baseline to pre-cycle 2 and decreased between pre-cycle 2 and pre-cycle 3; 177 these changes were not significant. There were no statistically significant associations between 178 baseline measures of cfDNA and outcome (PFS and OS) nor between changes in biomarker 179 levels and six-month PFS outcome (data not shown). 180
Circulating Tumor and Endothelial Cells 181
Whole blood was collected pre-cycles 1 (n=26), 2 (n=21), and 3 (n=12) for CTC and 182 CEC enumeration; CEC VEGFR expression was examined. Twenty-six patients were 183 evaluated for at least one time point; nine patients submitted samples at all three time points. 184
Median biomarker values are presented (Supplemental Table 3 ). Sixteen patients had >1 CTC 185 13 at one of the three timepoints, with nine patients having >1 at baseline. All patients had CECs 186 (range 14-800) at each timepoint tested. There were no statistically significant associations 187 between baseline CTCs or CECs and outcome (PFS and OS) nor between changes in 188 biomarker levels and six-month PFS outcome (data not shown). 189 CEC VEGFR expression was used to examine whether dasatinib had an effect on 190 endothelial cell activation and whether activation correlates with outcome. We anticipated the 191 percent of VEGFR+ CEC to decrease with a positive anti-angiogenic treatment effect. There 192 was no significant association between baseline CEC VEGFR expression and outcome (PFS 193 and OS) nor between changes in biomarker levels and six-month PFS outcome (data not 194 shown). 195 14 DISCUSSION 197 Dasatinib was well tolerated but had minimal activity in patients with recurrent ovarian or 198 primary peritoneal carcinoma. With SRC reported to be overexpressed in approximately 90% of 199 ovarian cancers [3] , no prescreening was performed to determine eligibility. 200 SRC occupies a strategic position in many cell signaling pathways affecting cell 201 proliferation, growth, and survival [4] . It has an important role in mediating the epithelial-to-202 mesenchymal transition enhancing the metastatic potential of ovarian cancer cells [15, 16] . 203 Activated SRC is required for VEGF expression, which has already been shown to be important 204 in ovarian cancer biology and as an important therapeutic target. SRC expression was 205 associated with a drug resistant phenotype and SRC inhibition by transfecting SRC antisense 206 oligonucleotides (or by small molecule inhibitors) reversed drug resistance in preclinical models 207 [6] . Gene expression profiles of ovarian cancer tumors were able to identify with greater than 208 80% accuracy which tumors were likely to be resistant to primary platinum-based therapy 209 [26, 27] . These profiles identified expression signatures consistent with activation of SRC which 210 in the future may be used to direct therapeutic strategies. 211 SRC protein expression usually correlated with the degree of SRC pathway 212 deregulation. The more deregulated the pathway, the higher the activated protein expression. 213
Platinum-resistant ovarian cancers have been shown to be more likely to have deregulation of 214 the SRC pathway [5, 26] . Kaplan-Meier survival analysis showed that SRC pathway 215 deregulation is associated with a poor survival. Konecny and colleagues tested a panel of 34 216 ovarian cancer cell lines and reported that 71% were highly sensitive to dasatinib [28] . rates of 4-5%. No or minimal activity also was observed in phase II trials of monotherapy 237 dasatinib in patients with head and neck cancer, glioma and small cell lung cancer (21, 31) . 238
None of these trials pre-selected patients based on any predictive biomarkers of dasatinib 239 activity. While SRC may be effective (under some circumstances) in suppressing tumor growth, 240 it is not able as monotherapy to cause regression of established tumors. There are 241 compensatory pathways that can bypass blockade of SRC. For example, SRC silencing results 242 in significant increase in FGR levels (another member of the SFK) [32] . Alternatively, activation 243 of JAK may re-establish downstream STAT signaling after inhibition of SFKs [33] . 244
The low activity of dasatinib as a single agent should not preclude evaluation as part of 245 combination regimens, either concomitantly or in sequence prior to chemotherapy if it is borne 246 out that dasatinib can serve a priming function in ovarian cancers with a high degree of SRC 247 pathway deregulation. In this regard, Pathak and Godwin have recently completed in vitro high-248 throughput screening (HTS) using a siRNA library targeting signaling molecules related to 249 receptor tyrosine kinases in combination with dasatinib. Such screening would identify second-250 site molecules that can be targeted in combination with SRC inhibition to synergistically improve 251 dasatinib efficacy in patients and to identify a potential gene signature predictive of response to 252 dasatinib therapy (personal communication). The clinical significance of these genes identified 253 through the HTS as being capable of synergizing with SRC inhibition is now being evaluated in 254 blinded tumor biopsy samples from the patients that participated in this trial. 255
Our correlative studies did not show any significance between the biomarkers tested and 256 patient outcome, mainly due to no clinical response on this study. There was a significant 257 increase in the levels of sVEGFR2, sVEGFR3, and IGFBP2 between baseline and pre-cycle 3 258 in the 15 patients submitting samples at all three time points similar to the data reported by 259 Strauss and colleagues [34] . There were no statistically significant changes in the three 260 housekeeping genes from baseline in these patients. The mechanisms of the occurrence of 261 cfDNA in blood under normal and pathological conditions are not yet fully understood. cfDNA 262 might be influenced by apoptosis, necrosis, decreased DNAase activity in circulating cancer 263 cells, as well as clearance by liver/kidney, and modification status of cfDNA. In this study, 16 264 patients had ≥1 CTC at one of the three time points; 9 had ≥1 at baseline. Further investigation 265 of the relationship between cfDNA and circulating CTCs and the predictive value of changes in 266 CTC in patients with ovarian cancer is needed.. Figure 1 : Kaplan-Meier plots for overall and progression-free survival.
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